NEWS & MEDIA · February 5, 2025

BioPharma APAC: R-biolin matches Novolin R in pre-clinical tests, gears up for 50× scale-up and human trials

This article summarizes coverage published on February 5, 2025.

BioPharma APAC reports that rBIO’s lead biosimilar insulin candidate, R‑biolin, achieved bioequivalence to Novo Nordisk’s Novolin® R in animal studies—an important validation step that clears the path for a 50‑fold manufacturing scale‑up and the first‑in‑human trials planned for later this year.

“R‑biolin matched Novolin® R in preclinical studies, validating its potential as a cost‑effective biosimilar insulin.” — BioPharma APAC.

Read the full article →

See how rBIO is transforming insulin affordability and access.

← Back to news

Contact rBIO for current information →